Back to discover
Drug

Dasiglucagon hydrochloride

Approved · EMA

Also known as Zegalogue, dasiglucagon (as hydrochloride), dasiglucagon HCl.

RxNorm2535234
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Zegalogue (EMA)

Regulatory2024-07-24EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Dasiglucagon hydrochloride
Aliases & brands
Zegaloguedasiglucagon (as hydrochloride)dasiglucagon HCl
RxNorm CUI
2535234
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2024-07-24
Latest approval
2024-07-24
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2024-07-24Approval
Approval: Zegalogue (EMA)

Indication: Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.